Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches

European Journal of Medicinal Chemistry

Volumn 114, Issue , 2016, Pages 41-58

  Salahuddin, Parveen ^a   Fatima, Munazza Tamkeen ^b   Abdelhameed, Ali Saber ^c   Nusrat, Saima ^a   Khan, Rizwan Hasan ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH BHOPAL   (India)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Alzheimer's disease; Amyloid oligomers; A channels; Fibrils; Parkinson's disease; Prion disease; Protein misfolding; Protofibrils

Indexed keywords

ACYLAMINO ACID RELEASING ENZYME; ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN; BETA SECRETASE 2; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CHANNEL BLOCKING AGENT; CHAPERONE; FREE RADICAL; ION CHANNEL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; OLEUROPEIN; OLIGOMER; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 1; PRION PROTEIN; PROTEIN AGGREGATE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; BETA SHEET; BINDING SITE; CALCIUM HOMEOSTASIS; CELL MEMBRANE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CYTOTOXICITY; DEGENERATIVE DISEASE; DEREGULATION; HYDROGEN BOND; HYDROPHOBICITY; LONG TERM POTENTIATION; MACROAUTOPHAGY; MEMBRANE CONDUCTANCE; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; NERVE CELL MEMBRANE; NEUROTOXICITY; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; PATHOLOGY; PRION DISEASES; PROTEIN CONFORMATION;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; HUMANS; MOLECULAR STRUCTURE; PARKINSON DISEASE; PRION DISEASES; PROTEIN CONFORMATION;

EID: 84964211691     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.02.065     Document Type: Review

References (264)

1. 3;: protein intrinsic disorder in degenerative diseases, Front. Biosci. 19 (2014) 181-258.
2. M. Stefani, Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world, Biochim. Biophys. Acta 24 (2004) 5-25.
3. R. Nelson, D. Eisenberg, Recent atomic models of amyloid fibril structure, Curr. Opin. Struct. Biol. 16 (2006) 260-265.
4. E.C. Gunther, S.M. Strittmatter, Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease, J. Mol. Med. 88 (2010) 331-338.
5. J. Hardy, K. Gwinn-Hardy, Genetic classification of primary neurodegenerative disease, Science 282 (1998) 1075-1079.
6. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, M. Liosatos, T.E. Morgan, I. Rozovsky, B. Trommer, K.L. Viola, P. Wals, C. Zhang, C.E. Finch, G.A. Krafft, W.L. Klein, Diffusible nonfibrillar ligands derived from Aβ 1-42 are potent central nervous system neurotoxins, Proc. Natl. Acad. Sci.U. S. A. 93 (1998) 6448-6453.
7. C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, A.I. Bush, C.L. Masters, Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease, Ann. Neurol. 46 (1999) 860-866.
8. D.J. Selkoe, Folding proteins in fatal ways, Nature 426 (2003) 900-904.
9. L. Breydo, V.N. Uversky, Structural, morphological, and functional diversity of amyloid oligomers, FEBS. Lett. 589 (2015) 2640-2648.
10. F.G. De Felice, M.N. Vieira, L.M. Saraiva, J.D. Figueroa-Villar, J. Garcia-Abreu, R. Liu, L. Chang, W.L. Klein, S.T. Ferreira, Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization, FASEB. J. 18 (2004) 1366-1372.
11. M. Caruana, T. Högen, J. Levin, A. Hillmer, A. Giese, N. Vassallo, Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds, FEBS. Lett. 585 (2011) 1113-1120.
12. V. Lopez-Miranda, M.L. Soto-Montenegro, G. Vera, E. Herradon, M. Desco, R. Abalo, Resveratrol: a neuroprotective polyphenol in the Mediterranean diet, Rev. Neurol. 54 (2012) 349-356.
13. J. Wang, L. Ho, W. Zhao, K. Ono, C. Rosensweig, L. Chen, N. Humala, D.B. Teplow, G.M. Pasinetti, Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease, 13 J, Neurosci 28 (2008) 6388-6392.
14. F. Visioli, A. Poli, C. Gall, Antioxidant and other biological activities of phenolsfrom olives and olive oil, Med. Res. Rev. 22 (2002) 65-75.
15. F. Visioli, S. Bellosta, C. Galli, Oleuropein, the bitter principle of olives, enhances nitric oxide production by mouse macrophages, Life, Sci. 62 (1998) 541-546.
16. I. Andreadou, E.K. Iliodromitis, E. Mikros, M. Constantinou, A. Agalias, P. Magiatis, A.L. Skaltsounis, E. Kamber, A. Tsantili-Kakoulidou, D.T. Kremastinos, The olive constituent oleuropein exhibits anti-ischemic, antioxidative, and hypolipidemic effects in anesthetized rabbits, J. Nutr. 136 (2006) 2213-2219.
17. H. Hatcher, R. Planalp, J. Cho, F.M. Torti, S.V. Torti, Curcumin: from ancient medicine to current clinical trials, Cell. mol.life. Sci. 65 (2008) 1631-1652.
18. A.R. Ladiwala, J.S. Dordick, P.M. Tessier, Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways, J. Biol. Chem. 286 (2011) 3209-3218.
19. K. Garai, P. Sengupta, B. Sahoo, S. Maiti, Selective destabilization of soluble amyloid beta oligomers by divalent metal ions, Biochem, Biophys. Res. Commun. 345 (2006) 210-215.
20. R. Scherzer-Attali, R. Shaltiel-Karyo, Y.H. Adalist, D. Segal, E. Gazit, Generic inhibition of amyloidogenic proteins by two naphthoquinone-tryptophan hybrid molecules, Proteins 80 (2012) 1962-1973.
21. R. Scherzer-Attali, D. Farfara, I. Cooper, A. Levin, T. Ben-Romano, D. Trudler, M. Vientrov, R. Shaltiel-Karyo, D.E. Shalev, N. Segev-Amzaleg, E. Gazit, D. Segal, D. Frenkel, Naphthoquinone-tyrptophan reduces neurotoxic Abetaz.ast;56 levels and improves cognition in Alzheimer's disease animal model, Neurobiol. Dis. 46 (2012) 663-672.
22. D.D. Soto-Ortega, B.P. Murphy, F.J. Gonzalez-Velasquez, K.A. Wilson, F. Xie, Q. Wang, M.A. Moss, Inhibition of amyloid-beta aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center, Bioorg. Med. Chem. 19 (2011) 2596-2602.
23. I. Granic, C. Nyakas, P.G. Luiten, U.L. Eisel, L.G. Halmy, G. Gross, H. Schoemaker, A. Moller, V. Nimmrich, Calpain inhibition prevents amyloidbeta-induced neurodegeneration and associated behavioral dysfunction in rats, Neuropharmacology 59 (2010) 334-342.
24. W. Zhao, J. Wang, L. Ho, K. Ono, D.B. Teplow, G.M. Pasinetti, Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization, Alzheimers. Dis. 16 (2009) 49-57.
25. A.F. McKoy, J. Chen, T. Schupbach, M.H. Hecht, A novel inhibitor of amyloid beta(Abeta) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease, J. Biol. Chem. 287 (2012) 38992-39000.
26. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, P. Seubert, Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature 400 (1999) 173-177.
27. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk, T. Yednock, Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nat. Med. 6 (2000) 916-919.
28. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, B.F. Michel, M. Boada, A. Frank, C. Hock, Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization, Neurology 61 (2003) 46-54.
29. R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul, D.M. Holtzman, Brain to plasmaamyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease, Science 295 (2002) 2264-2267.
30. J.C. Dodart, K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, C.A. DeLong, S. Wu, X. Wu, D.M. Holtzman, S.M. Paul, Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model, Nat. Neurosci. 5 (2002) 452-457.
31. C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, S.D. Schmidt, M.A. Chishti, P. Horne, D. Heslin, J. French, H.T. Mount, R.A. Nixon, M. Mercken, C. Bergeron, P.E. Fraser, P. St George-Hyslop, D. Westaway, A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature 408 (2000) 979-982.
32. J. McLaurin, R. Cecal, M.E. Kierstead, X. Tian, A.L. Phinney, M. Manea, J.E. French, M.H. Lambermon, A.A. Darabie, M.E. Brown, C. Janus, M.A. Chishti, P. Horne, D. Westaway, P.E. Fraser, H.T. Mount, M. Przybylski, P. St George-Hyslop, Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis, Nat. Med. 8 (2002) 1263-1269.
33. B. Solomon, R. Koppel, E. Hanan, T. Katzav, Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide, Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 452-455.
34. D.M. Walsh, I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, M.J. Rowan, D.J. Selkoe, Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal longterm potentiation in vivo, Nature 416 (2002) 535-539.
35. I. Klyubin, D.M. Walsh, C.A. Lemere, W.K. Cullen, G.M. Shankar, V. Betts, E.T. Spooner, L. Jiang, R. Anwyl, D.J. Selkoe, M.J. Rowan, Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo, Nat. Med. 11 (2005) 556-561.
36. M. Tayebi, D.R. Jones, W.A. Taylor, B.F. Stileman, C. Chapman, D. Zhao, M. David, PrP(Sc)-specific antibodies with the ability to immuno detect prion oligomers, PLoS. One 6 (2011) e19998.
37. V. Lindström, E. Ihse, T. Fagerqvist, J. Bergström, E. Nordström, C. Möller, L. Lannfelt, M. Ingelsson, Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders, Immunotherapy 6 (2014) 141-153.
38. E.A. Eckman, C.B. Eckman, A beta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention, Biochem. Soc. Trans. 33 (2005) 1101-1105.
39. M.A. Leissring, The AβCs of Aβ-cleaving proteases, J. Biol. Chem. 283 (2008) 29645-29649.
40. M.A. Leissring, T.C. Saido, Aβ degradation, in: S. Sisodia, R. Tanzi (Eds.), In Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology, Springer, New York, 2007, pp. 157-178.
41. A.J. Turner, N.N. Nalivaeva, New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection, Int. Rev. Neurobiol. 82 (2007) 113-135.
42. S. Howell, J. Nalbantoglu, P. Crine, Neutral endopeptidase can hydrolyze bamyloid(1-40) but shows no effect on β-amyloid precursor protein metabolism, Peptides 16 (1995) 647-652.
43. L.B. Hersh, D.W. Rodgers, Neprilysin and amyloid beta peptide degradation, Curr. Alzheimer. Res. 5((2008) 225-231.
44. N. Iwata, S. Tsubuki, Y. Takaki, K. Shirotani, B. Lu, N.P. Gerard, C. Gerard, E. Hama, H.J. Lee, T.C. Saido, Metabolic regulation of brain Abeta by neprilysin, Science 292 (2001) 1550-1552.
45. M.A. Leissring, W. Farris, A.Y. Chang, D.M. Walsh, X. Wu, X. Sun, M.P. Frosch, D.J. Selkoe, Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death, Neuron 40 (2003) 1087-1093.
46. S.M. Huang, A. Mouri, H. Kokubo, R. Nakajima, T. Suemoto, M. Higuchi, M. Staufenbiel, Y. Noda, H. Yamaguchi, T. Nabeshima, T.C. Saido, N. Iwata, Neprilysin-sensitive synapse associated amyloid-β peptide oligomers impair neuronalplasticity and cognitive function, J. Biol. Chem. 281 (2006) 17941-17951.
47. W.J. Meilandt, M. Cisse, K. Ho, T. Wu, L.A. Esposito, K. Scearce-Levie, I.H. Cheng, G.Q. Yu, L. Mucke, Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice, J. Neurosci. 29 (2009) 1977-1986.
48. H. Kanemitsu, T. Tomiyama, H. Mori, Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form, Neurosci. Lett. 350 (2003) 113-116.
49. K. Shirotani, S. Tsubuki, N. Iwata, Y. Takaki, W. Harigaya, K. Maruyama, S. Kiryu-Seo, H. Kiyama, H. Iwata, T. Tomita, T. Iwatsubo, T.C. Saido, Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases, J. Biol. Chem. 276 (2001) 21895-21901.
50. D. Hafez, J.Y. Huang, A.M. Huynh, S. Valtierra, E. Rockenstein, A.M. Bruno, B. Lu, L. DesGroseillers, E. Masliah, R.A. Marr, Neprilysin-2 is an important beta-amyloid degrading enzyme, Am. J. Pathol. 178 (2011) 306-312.
51. J.Y. Huang, A.M. Bruno, C.A. Patel, A.M. Huynh, K.D. Philibert, M.J. Glucksman, R.A. Marr, Human membrane metallo-endopeptidase-like protein degrades both betaamyloid 42 and beta-amyloid 40, Neuroscience 155 (2008) 258-262.
52. E.A. Eckman, D.K. Reed, C.B. Eckman, Degradation of the Alzheimer's amyloid beta peptide by endothelin converting enzyme, J. Biol. Chem. 276 (2001) 24540-24548.
53. E.A. Eckman, M. Watson, L. Marlow, K. Sambamurti, C.B. Eckman, Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelinconverting enzyme, J. Biol. Chem. 278 (2003) 2081-2084.
54. W.E. Van Nostrand, M. Porter, Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity, Biochemistry 38 (1999) 11570-11576.
55. H.M. Tucker, M. Kihiko-Ehmann, S. Wright, R.E. Rydel, S. Estus, Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition, J. Neurochem. 75 (2000) 2172-2177.
56. R. Yamin, S. Bagchi, R. Hildebrant, A. Scaloni, R.L. Widom, C.R. Abraham, Acyl peptide hydrolase, a serine proteinase isolated from conditioned medium of neuroblastoma cells, degrades the amyloid-beta peptide, J. Neurochem. 100 (2007) 458-467.
57. R. Yamin, C. Zhao, P.B. O'Connor, A.C. McKee, C.R. Abraham, Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide, Mol. Neurodegener. 4 (2009) 33.
58. S.A. Frautschy, D.L. Horn, J.J. Sigel, M.E. Harris-White, J.J. Mendoza, F. Yang, T.C. Saido, G.M. Cole, Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain, J. Neurosci. 18 (1998) 8311-8321.
59. S. Mueller-Steiner, Y. Zhou, H. Arai, E.D. Roberson, B. Sun, J. Chen, X. Wang, G. Yu, L. Esposito, L. Mucke, L. Gan, Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease, Neuron 51 (2006) 703-714.
60. R. Fluhrer, G. Multhaup, A. Schlicksupp, M. Okochi, M. Takeda, S. Lammich, M. Willem, G. Westmeyer, W. Bode, J. Walter, C. Haass, Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin dependent generation, J. Biol. Chem. 278 (2003) 5531-5538.
61. E.B. Lee, B. Zhang, K. Liu, E.A. Greenbaum, R.W. Doms, J.Q. Trojanowski, V.M. Lee, BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo, J. Cell. Biol. 168 (2005) 291-302.
62. S.O. Abdul-Hay, M.A. Leissring, Functional cDNAscreening identifies BACE-2 as a principal beta-amyloiddegrading protease. In Alzheimer's Association International Conference on Alzheimer's disease, Proposal No 17630 (2011AAIC), Paris.
63. T. Saido, M.A. Leissring, Proteolytic degradation of amyloid β-protein Cold, Spring. Harb. Perspect. Med. 2 (2012) a006379.
64. D. Dominguez, J. Tournoy, D. Hartmann, T. Huth, K. Cryns, S. Deforce, L. Serneels, I.E. Camacho, E. Marjaux, K. Craessaerts, A.J. Roebroek, M. Schwake, R. D'Hooge, P. Bach, U. Kalinke, D. Moechars, C. Alzheimer, K. Reiss, P. Saftig, B. De Strooper, Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice, J. Biol. Chem. 280 (2005) 30797-30806.
65. T. Wyss-Coray, J. Loike, T.C. Brionne, E. Lu, R. Anankov, F. Yan, S.C. Silverstein, J. Husemann, Adult mouse astrocytes degrade amyloid-beta in vitro and in situ, Nat. Med. 9 (2003) 453-457.
66. H. Taguchi, S. Planque, Y. Nishiyama, P. Szabo, M.E. Weksler, R.P. Friedland, S. Paul, Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease, Autoimmun. Rev. 7 (2008a) 391-397.
67. H. Taguchi, S. Planque, G. Sapparapu, S. Boivin, M. Hara, Y. Nishiyama, S. Paul, Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds, J. Biol. Chem. 283 (2008b) 36724-36733.
68. C. Soto, E.M. Sigurdsson, L. Morelli, R.A. Kumar, E.M. Castaño, B. Frangione, Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy, Nat. Med. 4 (1998) 822-826.
69. C. Soto, Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches, J. Mol. Med. 77 (1999) 412-418.
70. J.F. Poduslo, G.L. Curran, A. Kumar, B. Frangione, C. Soto, Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma, J. Neurobiol. 39 (1999) 371-382.
71. C. Soto, R.J. Kascsak, G.P. Saborío, P. Aucouturier, T. Wisniewski, F. Prelli, R. Kascsak, E. Mendez, D.A. Harris, J. Ironside, F. Tagliavini, R.I. Carp, B. Frangione, Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides, Lancet 355 (2000) 192-197.
72. N. Arispe, H.B. Pollard, E. Rojas, Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes, Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10573-10577.
73. H.B. Pollard, E. Rojas, N. Arispe, A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid beta protein (A beta P) in phospholipid bilayer membranes, Ann. N. Y. Acad. Sci. 695 (1993) 165-168.
74. N. Arispe, H.B. Pollard, E. Rojas, Beta-Amyloid Ca (2+)-channel hypothesis for neuronal death in Alzheimer disease, Mol. Cell. Biochem. 140 (1994) 119-125.
75. 2+ interaction with Alzheimer amyloid beta protein calcium channels, Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1710-1715.
76. H. Lin, R. Bhatia, R. Lal, Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology, FASEB. J. 15 (2001) 2433-2444.
77. H.A. Lashuel, D. Hartley, B.M. Petre, T. Walz, P.T. Lansbury Jr., Neurodegenerative disease: amyloid pores from pathogenic mutations, Nature 418 (2002) 291.
78. A. Quist, I. Doudevski, H. Lin, R. Azimova, D. Ng, B. Frangione, B. Kagan, J. Ghiso, R. Lal, Amyloid ion channels: a common structural link for proteinmisfolding disease, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10427-10432.
79. H. Jang, J. Zheng, R. Nussinov, Models of beta-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process, Biophys. J. 93 (2007) 1938-1949.
80. H. Jang, J. Zheng, R. Lal, R. Nussinov, New structures help the modeling of toxic amyloidbeta ion channels, Trends, Biochem. Sci. 33 (2008) 91-100.
81. H. Jang, F.T. Arce, R. Capone, S. Ramachandran, R. Lal, R. Nussinov, Misfolded amyloid ion channels present mobile beta-sheet subunits in contrast to conventional ion channels, Biophys. J. 97 (2009) 3029-3037.
82. H. Jang, F.T. Arce, S. Ramachandran, R. Capone, R. Azimova, B.L. Kagan, R. Nussinov, R. Lal, Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome, Proc. Natl. Acad. Sci. U.S.A. 107 (2010) 6538-6543.
83. H. Jang, F.T. Arce, S. Ramachandran, R. Capone, R. Lal, R. Nussinov, Structural convergence among diverse, toxic beta-sheet ion channels, J. Phys. Chem. B 114 (2010) 9445-9451.
84. H. Jang, F.T. Arce, S. Ramachandran, R. Capone, R. Lal, R. Nussinov, β-Barrel topology of Alzheimer's β-amyloid ion channels, J. Mol. Biol. 404 (2010) 917-934.
85. R. Capone, H. Jang, S.A. Kotler, L. Connelly, F. Teran Arce, S. Ramachandran, B.L. Kagan, R. Nussinov, R. Lal, All-d-enantiomer of β-amyloid peptide forms ion channels in lipid bilayers, J. Chem. Theory. Comput. 8 (2012) 1143-1152.
86. R. Capone, H. Jang, S.A. Kotler, B.L. Kagan, R. Nussinov, R. Lal, Probing structural features of Alzheimer's amyloid-β pores in bilayers using sitespecific amino acid substitutions, Biochemistry 51 (2012) 776-785.
87. L. Connelly, H. Jang, F.T. Arce, R. Capone, S.A. Kotler, S. Ramachandran, B.L. Kagan, R. Nussinov, R. Lal, Atomic force microscopy and MD simulations reveal pore-like structures of all-D-enantiomer of Alzheimer's β-amyloid peptide: relevance to the ion channel mechanism of AD pathology, J. Phys. Chem. B 116 (2012) 1728-1735.
88. L. Connelly, H. Jang, F.T. Arce, S. Ramachandran, B.L. Kagan, R. Lal, Effects of point substitutions on the structure of toxic Alzheimer's β-amyloid channels: atomic force microscopy and molecular dynamics simulations, Biochemistry 51 (2012) 3031-3038.
89. J.C. Diaz, O. Simakova, K.A. Jacobson, N. Arispe, H.B. Pollard, Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity, Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 3348-3353.
90. T.S. Anekonda, J.F. Quinn, C. Harris, K. Frahler, T.L. Wadsworth, R.L. Woltjer, L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease, Neurobiol. Dis. 41 (2011) 62-70.
91. M.K. Sandberg, P. Wallen, M.A. Wikstrom, K. Kristensson, Scrapie-infected GT-1 cells show impaired function of voltage-gated N-type calcium channels (Ca(v) 2.2) which is ameliorated by quinacrine treatment, Neurobiol. Dis. 15 (2004) 143-151.
92. B. Pasternak, H. Svanström, N.M. Nielsen, L. Fugger, M. Melbye, A. Hviid, Use of calcium channel blockers and Parkinson's disease, Am. J. Epidemiol. 175 (2012) 627-635.
93. J. Kumar, R. Namsechi, V.L. Sim, Structure-based peptide design to modulate amyloid beta aggregation and reduce cytotoxicity, PLoS. One 10 (2015) e0129087.
94. C. Barucker, H.J. Bittner, P.K. Chang, S. Cameron, M.A. Hancock, F. Liebsch, S. Hossain, A. Harmeier, H. Shaw, F.M. Charron, M. Gensler, P. Dembny, W. Zhuang, D. Schmitz, J.P. Rabe, Y. Rao, R. Lurz, P.W. Hildebrand, R.A. McKinney, G. Multhaup, Aβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function, Sci. Rep. 5 (2015) 15410.
95. M. Sunde, C. Blake, The structure of amyloid fibrils by electron microscopy and X-ray diffraction, Adv, Protein. Chem. 50 (1997) 123-159.
96. C.M. Dobson, Protein misfolding, evolution and disease, Trends. Biochem. Sci. 24 (1999) 329-332.
97. L.C. Serpell, M. Sunde, M.D. Benson, G.A. Tennent, M.B. Pepys, P.E. Fraser, The protofilament substructure of amyloid fibrils, J. Mol. Biol. 300 (2000) 1033-1039.
98. H.H. Bauer, U. Aebi, M. Häner, R. Hermann, M. Müller, H.P. Merkle, Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin, J. Struct. Biol. 115 (1995) 1-15.
99. M. Saiki, S. Honda, K. Kawasaki, D. Zhou, A. Kaito, T. Konakahara, H. Morii, Higher-order molecular packing in amyloid-like fibrils constructed with linear arrangements of hydrophobic and hydrogen-bonding side-chains, J. Mol. Biol. 348 (2005) 983-998.
100. A.T. Petkova, Y. Ishii, M.J. Balbach, O.N. Antzutkin, R.D. Leapman, F. Delaglio, R. Tycko, A structural model for Alzheimer's beta amyloid fibrils based on experimental constraints from solid state NMR, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16742-16747.
101. C. Liu, M. Zhao, L. Jiang, P.N. Cheng, J. Park, M.R. Sawaya, A. Pensalfini, D. Gou, A.J. Berk, C.G. Glabe, J. Nowick, D. Eisenberg, Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates, Proc. Natl. Acad. Sci. U.S.A. 109 (2012) 20913-20918.
102. M.R. Sawaya, S. Sambashivan, R. Nelson, M.I. Ivanova, S.A. Sievers, M.I. Apostol, M.J. Thompson, M. Balbirnie, J.J. Wiltzius, H.T. McFarlane, A.O. Madsen, C. Riekel, D. Eisenberg, Atomic structures of amyloid cross-beta spines reveal varied steric zippers, Nature 447 (2007) 453-457.
103. J.T. Nielsen, M. Bjerring, M.D. Jeppesen, R.O. Pedersen, J.M. Pedersen, K.L. Hein, T. Vosegaard, T. Skrydstrup, D.E. Otzen, N.C. Nielsen, Unique identification of supramolecular structures in amyloid fibrils by solid-state NMRspectroscopy, Angew. Chem. Int. Ed. Engl. 48 (2009) 2118-2121.
104. G.T. Westermark, K.H. Johnson, P. Westermark, Staining methods for identification of amyloid in tissue, Methods. Enzymol. 309 (1999) 3-25.
105. C.S. Goldsbury, S. Wirtz, S.A. Müller, S. Sunderji, P. Wicki, U. Aebi, P. Frey, Studies on the in vitro assembly of Aβ 1-40: implications for the search for Aβ fibril formation inhibitors, J. Struct. Biol. 130 (2000) 217-231.
106. D.M. Walsh, D.M. Hartley, Y. Kusumoto, Y. Fezoui, M.M. Condron, A. Lomakin, G.B. Benedek, D.J. Selkoe, D.B. Teplow, Amyloid β-protein fibrillogenesis, J. Biol. Chem. 274 (1999) 25945-25952.
107. G. Habicht, C. Haupt, R.P. Friedrich, P. Hortschansky, C. Sachse, J. Meinhardt, K. Wieligmann, G.P. Gellermann, M. Brodhun, J. Götz, K.J. Halbhuber, C. Röcken, U. Horn, M. Fändrich, Directed selection of a conformational antibody domain thatprevents mature amyloid fibril formation by stabilizing Aβ protofibrils, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19232-19237.
108. H.A. Scheidt, I. Morgado, S. Rothemund, D. Huster, M. Fändrich, Solid-state NMR spectroscopic investigation of Aβ protofibrils: implication of a β-sheet remodeling upon maturation into terminal amyloid fibrils, Angew. Chem. Int. Ed. Engl. 50 (2011) 2837-2840.
109. H.A. Lashuel, D.M. Hartley, B.M. Petre, T. Walz, P.T. Lansbury, Neurodegenerative disease:amyloid pores from pathogenic mutations, Nature 418 (2002) 291.
110. B. Caughey, P.T. Lansbury, Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocentbystanders, Annu. Rev. Neurosci. 26 (2003) 267-298.
111. H.A. Lashuel, D.M. Hartley, B.M. Petre, J.S. Wall, M.N. Simon, T. Walz, P.T. Lansbury Jr., Mixtures of wildtype and a pathogenic (E22G) form of Aβ40 in vitro accumulate protofibrils, including amyloid pores, J. Mol. Biol. 332 (2003) 795-808.
112. S.M. Butterfield, H.A. Lashuel, Amyloidogenic protein-membrane interactions: mechanistic insight from model systems, Angew. Chem. Int. Ed. Engl. 49 (2010) 5628-5654.
113. R. Diaz-Espinoza, C. Soto, High-resolution structure of infectious prion protein: the final frontier, Nat. Struct. Mol. Biol. 19 (2012) 370-377.
114. R. Nelson, D. Eisenberg, Structural models of amyloid-like fibrils, Adv. Protein. Chem. 73 (2006) 235-282.
115. R. Tycko, R.B. Wickner, Molecular structures of amyloid and prion fibrils: consensus versus controversy, Acc. Chem. Re 46 (2013) 1487-1496.
116. D. Eisenberg, M. Jucker, The amyloid state of proteins in human diseases, Cell. 148 (2012) 1188-1203.
117. D.V. Laurents, P.M. Gorman, M. Guo, M. Rico, A. Chakrabartty, M. Bruix, Alzheimer's Abeta40 studied by NMR at low pH reveals that sodium 4,4-dimethyl-4-silapentane-1-sulfonate (DSS) binds and promotes beta-ball oligomerization, J. Biol. Chem. 280 (2005) 3675-3685.
118. L. Yu, R. Edalji, J.E. Harlan, T.F. Holzman, A.P. Lopez, B. Labkovsky, H. Hillen, S. Barghorn, U. Ebert, P.L. Richardson, L. Miesbauer, L. Solomon, D. Bartley, K. Walter, R.W. Johnson, P.J. Hajduk, E.T. Olejniczak, Structural characterization of a soluble amyloid beta-peptide oligomer, Biochemistry 48 (2009) 1870-1877.
119. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, C.G. Glabe, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science 300 (2003) 486-489.
120. T.H. Huang, D.S. Yang, N.P. Plaskos, S. Go, C.M. Yip, P.E. Fraser, A. Chakrabartty, Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide, J. Mol. Biol. 297 (2000) 73-87.
121. A.D. Williams, M. Sega, M. Chen, I. Kheterpal, M. Geva, V. Berthelier, D.T. Kaleta, K.D. Cook, R. Wetzel, Structural properties of Abeta protofibrils stabilized by a small molecule, Proc. Nat. Acad. Sci. U.S.A. 102 (2005) 7115-7120.
122. D. Losic, L. L. Martin, A. Mechler, M.I. Aguilar, D.H. Small, High resolution scanning tunnelling microscopy of the beta-amyloid protein (Abeta1-40) of Alzheimer's disease suggests a novel mechanism of oligomer assembly, J. Struct. Biol. 155 (2006) 104-110.
123. K. Ono, M.M. Condron, D.B. Teplow, Structure-neurotoxicity relationships of amyloid beta-protein oligomers, Proc. Nat. Acad. U. S. A. 106 (2009) 14745-14750.
124. J. Janson, R.H. Ashley, D. Harrison, S. McIntyre, P.C. Butler, The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediatesized toxic amyloid particles, Diabetes 48 (1999) 491-498.
125. K.A. Conway, J.D. Harper, P.T. Lansbury Jr., Fibrils formed in vitro from alphasynuclein and two mutant forms linked to Parkinson's disease are typical amyloid, Biochemistry 39 (2000) 2552-2563.
126. S. Chimon, M.A. Shaibat, C.R. Jones, D.C. Calero, B. Aizezi, Y. Ishii, Evidence of fibril-like beta-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's beta-amyloid, Nat. Struct. Mol. Biol. 14 (2007) 1157-1164.
127. M. Ahmed, J. Davis, D. Aucoin, T. Sato, S. Ahuja, S. Aimoto, J.I. Elliott, W.E. Van Nostrand, S.O. Smith, Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils, Nat. Struct. Mol. Biol. 17 (2010) 561-567.
128. E. Cerf, R. Sarroukh, S. Tamamizu-Kato, L. Breydo, S. Derclaye, Y.F. Dufrêne, V. Narayanaswami, E. Goormaghtigh, J.M. Ruysschaert, V. Raussens, Antiparallel beta-sheet: a signature structure of the oligomeric amyloid betapeptide, Biochem. J. 421 (2009) 415-423.
129. A. Eckert, S. Hauptmann, I. Scherping, J. Meinhardt, V. Rhein, S. Dröse, U. Brandt, M. Fändrich, W.E. Müller, J. Götz, Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice, J. Mol. Med. 86 (2008) 1255-1267.
130. K. Broersen, F. Rousseau, J. Schymkowitz, The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimers. Res. Ther. 2 (2010) 12.
131. L. Gu, C. Liu, J.C. Stroud, S. Ngo, L. Jiang, Z. Guo, Antiparallel triple-strand architecture for prefibrillar Aβ42 oligomers, J. Biol. Chem. 289 (2014) 27300-27313.
132. P. Walsh, J. Yau, K. Simonetti, S. Sharpe, Morphology and secondary structure of stable beta-oligomers formed by amyloid peptide PrP(106-126), Biochemistry 48 (2009) 5779-5781.
133. P. Huang, F. Lian, Y. Wen, C. Guo, D. Lin, Prion protein oligomer and its neurotoxicity, Acta. Biochim. Biophys. Sin. (Shanghai) 45 (2013) 442-445.
134. P.H. Weinreb, W. Zhen, A.W. Poon, K.A. Conway, P.T. Lansbury Jr., NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded, Biochemistry 35 (1996) 13709-13715.
135. C.W. Bertoncini, Y.S. Jung, C.O. Fernandez, W. Hoyer, C. Griesinger, T.M. Jovin, M. Zweckstetter, Release of long-range tertiary interactions potentiates aggregation of natively unstructured α-synuclein, Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 1430-1435.
136. L.C. Serpell, J. Berriman, R. Jakes, M. Goedert, R.A. Crowther, Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation, Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4897-4902.
137. M. Chen, M. Margittai, J. Chen, R. Langen, Investigation of α-synucleinfibril structure by site-directed spin labeling, J. Biol. Chem. 282 (2007) 24970-24979.
138. H. Heise, W. Hoyer, S. Becker, O.C. Andronesi, D. Riedel, M. Baldus, Molecular-level secondary structure, polymorphism, and dynamics of full-lengthαsynuclein fibrils studied by solid-state NMR, Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 15871-15876.
139. S.J. Wood, J. Wypych, S. Steavenson, J.C. Louis, M. Citron, A.L. Biere, α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease, J. Biol. Chem. 274 (1999) 19509-19512.
140. A.L. Fink, The aggregation and fibrillation of α-synuclein, Acc. Chem. Res. 39 (2006) 628-634.
141. H.A. Lashuel, B.M. Petre, J. Wall, M. Simon, R.J. Nowak, T. Walz, P.T. Lansbury Jr., Alpha synuclein, especially the Parkinson's diseaseassociated mutants, forms pore-like annular and tubular protofibrils, J. Mol. Biol. 322 (2002) 1089-1102.
142. R. Kayed, E. Head, F. Sarsoza, T. Saing, C.W. Cotman, M. Necula, L. Margol, J. Wu, L. Breydo, J.L. Thompson, S. Rasool, T. Gurlo, P. Butler, C.G. Glabe, Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers, Mol. Neurodegener. 2 (2007) 18.
143. M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou, A.L. Fink, The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils, J. Biol. Chem. 279 (2004) 26846-26857.
144. D.P. Hong, A.L. Fink, V.N. Uversky, Structural characteristics of alpha synuclein oligomers stabilized by the flavonoid baicalein, J. Mol. Biol. 383 (2008) 214-223.
145. M.S. Celej, R. Sarroukh, E. Goormaghtigh, G.D. Fidelio, J.M. Ruysschaert, V. Raussens, Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure, Biochem. J. 443 (2012) 719-726.
146. S. Chimon, Y. Ishii, Capturing intermediate structures of Alzheimer's betaamyloid, Abeta(1-40), by solid-state NMR spectroscopy, J. Am. Chem. Soc. 127 (2005) 13472-13473.
147. N. Arispe, Architecture of the Alzheimer's A beta P ion channel pore, J. Membr. Biol. 197 (2004) 33-48.
148. R. Kayed, C.A. Lasagna-Reeves, Molecular mechanisms of amyloid oligomers toxicity, J. Alzheimers. Dis. 33 (2013) S67-S78.
149. M. Kawahara, Y. Kuroda, N. Arispe, E. Rojas, Alzheimer's beta-Amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line, J. Biol. Chem. 275 (2000) 14077-14083.
150. B.L. Kagan, R. Azimov, R. Azimova, Amyloid peptide channels, J. Membr. Biol. 202 (2004) 1-10.
151. B.L. Kagan, Y. Hirakura, R. Azimov, R. Azimova, M.C. Lin, The channel hypothesis of Alzheimer's disease: current status, Peptides 23 (2002) 1311-1315.
152. S.M. Yatin, M. Aksenova, M. Aksenov, W.R. Markesbery, T. Aulick, D.A. Butterfield, Temporal relations among amyloid beta-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses, J. Mol. Neurosci. 11 (1998) 183-197.
153. A. Takashima, K. Noguchi, K. Sato, T. Hoshino, K. Imahori, Tau protein kinase I is essential for amyloid beta protein-induced neurotoxicity, Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 7789-7793.
154. M. Kawahara, I. Ohtsuka, S. Yokoyama, M. Kato-Negishi, Y. Sadakane, Membrane incorporation, channel formation, and disruption of calcium homeostasis by Alzheimer's β-amyloid protein, Int. J. Alzheimers. Dis. 12 (2011) 304583.
155. R. Kayed, Y. Sokolov, B. Edmonds, T.M. McIntire, S.C. Milton, J.E. Hall, C.G. Glabe, Permeabilization of lipid bilayersis a common conformation-dependent activity of solubleamyloid oligomers in protein misfolding diseases, J. Biol. Chem. 279 (2004) 46363-46366.
156. R. Kayed, A. Pensalfini, L. Margol, Y. Sokolov, F. Sarsoza, E. Head, J. Hall, C. Glabe, Annular protofibrils are a structurally and functionally distinct type of amyloidoligomer, J. Biol. Chem. 284 (2009) 4230-4237.
157. W.L. Klein, W.B. Stine Jr., D.B. Teplow, Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease, Neurobiol. Aging 25 (2004) 569-580.
158. M. Stefani, C.M. Dobson, Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution, J. Mol. Med. 81 (2003) 678-699.
159. D. M. Walsh, D.J. Selkoe, Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration, Protein. Pept. Lett. 11 (2004) 213-228.
160. A. Demuro, E. Mina, R. Kayed, S.C. Milton, I. Parker, C.G. Glabe, Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers, J. Biol. Chem. 280 (2005) 17294-17300.
161. Y. Porat, S. Kolusheva, R. Jelinek, E. Gazit, The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies, Biochemistry 42 (2003) 10971-10977.
162. C. Canale, S. Torrassa, P. Rispoli, A. Relini, R. Rolandi, M. Bucciantini, M. Stefani, A. Gliozzi, Natively folded HypF-N and its early amyloid aggregates interact with phospholipid monolayers and destabilize supported phospholipid bilayers, Biophys. J. 91 (2006) 4575-4588.
163. H.A. Lashuel, P.T. Lansbury Jr., Are amyloid diseases caused by protein aggregates that mimic bacterial poreforming toxins? Q. Rev. Biophys. 39 (2006) 167-201.
164. M.J. Volles, S.J. Lee, J.C. Rochet, M.D. Shtilerman, T.T. Ding, J.C. Kessler, P.T. Lansbury Jr., Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease, Biochemistry 40 (2001) 7812-7819.
165. G. Valincius, F. Heinrich, R. Budvytyte, D.J. Vanderah, D.J. McGillivray, Y. Sokolov, J.E. Hall, M. Losche, Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity, Biophys. J. 95 (2008) 4845-4861.
166. J.D. Green, L. Kreplak, C. Goldsbury, X. LifBlatter, M. Stolz, G.S. Cooper, A. Seelig, J. Kistler, U. Aebi, J. Mol. Biol. 342 (2004) 877-887.
167. Y. Sokolov, J.A. Kozak, R. Kayed, A. Chanturiya, C. Glabe, J.E. Hall, Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure, J. Gen. Physiol. 128 (2006) 637-647.
168. J. Hannig, D. Zhang, D.J. Canaday, M.A. Beckett, R.D. Astumian, R.R. Weichselbaum, R.C. Lee, Surfactant sealing of membranes permeabilized by ionizing radiation, Radiat. Res. 154 (2000) 171-177.
169. R. Kayed, C.A. Lasagna-Reeves, in: D. Philippe (Ed.), Alzheimer's Disease, Imperial College Press, London, 2013.
170. M. Bucciantini, G. Calloni, F. Chiti, L. Formigli, D. Nosi, C.M. Dobson, M. Stefani, Prefibrillar amyloid protein aggregates share common features of cytotoxicity, J. Biol. Chem. 279 (2004) 31374-31382.
171. E.M. Snyder, Y. Nong, C.G. Almeida, S. Paul, T. Moran, E.Y. Choi, A.C. Nairn, M.W. Salter, P.J. Lombroso, G.K. Gouras, P. Greengard, Regulation of NMDA receptor trafficking by amyloid-beta, Nat. Neurosci. 8 (2005) 1051-1058.
172. N. Yamamoto, E. Matsubara, S. Maeda, H. Minagawa, A. Takashima, W. Maruyama, M. Michikawa, K. Yanagisawa, A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation, J. Biol. Chem. 282 (2007) 2646-2655.
173. G. Yamin, NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus, J. Neurosci. Res. 87 (2009) 1729-1736.
174. C. Glabe, Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease, J. Mol. Neurosci. 17 (2001) 137-145.
175. F.M. LaFerla, K.N. Green, S. Oddo, Intracellular amyloid-beta in Alzheimer's disease, Nat. Rev. Neurosci. 8 (2007) 499-509.
176. G.K. Gouras, D. Tampellini, R.H. Takahashi, E. Capetillo-Zarate, Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease, Acta. Neuropathol. 119 (2010) 523-541.
177. M.R. D'Andrea, R.G. Nagele, H.Y. Wang, P.A. Peterson, D.H. Lee, Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease, Histopathology 38 (2001) 120-134.
178. D.M. Skovronsky, R.W. Doms, V.M. Lee, Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture, J. Cell. Biol. 141 (1998) 1031-1039.
179. C.G. Almeida, D. Tampellini, R.M. Takahashi, P. Greengard, M.T. Lin, E.M. Snyder, G.K. Gouras, Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses, Neurobiol. Dis. 20 (2005) 187-198.
180. C. Casas, N. Sergeant, J.M. Itier, V. Blanchard, O. Wirths, N. van der Kolk, V. Vingtdeux, E. van de Steeg, G. Ret, T. Canton, H. Drobecq, A. Clark, B. Bonici, A. Delacourte, J. Benavides, C. Schmitz, G. Tremp, T.A. Bayer, P. Benoit, L. Pradier, Massive CA1/2 neuronal loss with intraneuronal and Nterminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model, Am. J. Pathol. 165 (2004) 1289-1300.
181. D.L. Moolman, O.V. Vitolo, J.P. Vonsattel, M.L. Shelanski, Dendrite and dendritic spine alterations in Alzheimermodels, J. Neurocytol. 33 (2004) 377-387.
182. C. Mori, E.T. Spooner, K.E. Wisniewsk, T.M. Wisniewski, H. Yamaguch, T.C. Saido, D.R. Tolan, D.J. Selkoe, C.A. Lemere, Intraneuronal Abeta42 accumulation in down syndromebrain, Amyloid 9 (2002) 88-102.
183. L. Mucke, E. Masliah, G.Q. Yu, M. Mallory, E.M. Rockenstein, G. Tatsuno, K. Hu, D. Kholodenko, K. Johnson-Wood, L. McConlogue, High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation, J. Neurosci. 20 (2000) 4050-4058.
184. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, R. Metherate, M.P. Mattson, Y. Akbari, F.M. LaFerla, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron 39 (2003) 409-421.
185. T.L. Spires, M. Meyer-Luehmann, E.A. Stern, T.J. McLean, J. Skoch, P.T. Nguyen, B.J. Bacskai, B.T. Hyman, Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy, J. Neurosci. 25 (2005) 7278-7287.
186. R.H. Takahashi, T.A. Milner, F. Li, E.E. Nam, M.A. Edgar, H. Yamaguchi, M.F. Beal, H. Xu, P. Greengard, G.K. Gouras, Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology, Am. J. Pathol. 161 (2002) 1869-1879.
187. C.G. Almeida, R.H. Takahashi, G.K. Gouras, Betaamyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system, J. Neurosci. 26 (2006) 4277-4288.
188. S. Oh, H.S. Hong, E. Hwang, H.J. Sim, W. Lee, S.J. Shin, I. Mook-Jung, Amyloid peptide attenuates the proteasome activity in neuronal cells, Mech. Ageing. Dev. 126 (2005) 1292-1299.
189. B.P. Tseng, K.N. Green, J.L. Chan, M. Blurton-Jones, F.M. LaFerla, Abeta inhibits the proteasome and enhances amyloid and tau accumulation, Neurobiol. Aging 29 (2008) 1607-1618.
190. M. Manczak, T.S. Anekonda, E. Henson, B.S. Park, J. Quinn, P.H. Reddy, Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression, Hum. Mol. Genet. 15 (2006) 1437-1449.
191. S. Varadarajan, S. Yatin, M. Aksenova, D.A. Butterfield, Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity, J. Struct. Biol. 130 (2000) 184-208.
192. D.A. Butterfield, T. Reed, S.F. Newman, R. Sultana, Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment, Free. Radic. Biol. Med. 43 (2007) 658-677.
193. D.G. Jo, T.V. Arumugam, H.N. Woo, J.S. Park, S.C. Tang, M. Mughal, D.H. Hyun, J.H. Park, Y.H. Choi, A.R. Gwon, et al., Evidence that gama-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease, Neurobiol. Aging 31 (2010) 917-925.
194. L. Zheng, K. Kågedal, N. Dehvari, E. Benedikz, R. Cowburn, J. Marcusson, A. Terman, Oxidative stress induces macroautophagy of amyloid β-protein and ensuing apoptosis, Free. Radic. Biol. Med. 46 (2009) 422-429.
195. H.M. Abdul, D.A. Butterfield, Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyll-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease, Free. Radic. Biol. Med. 42 (2007) 371-384.
196. M. Naoi, W. Maruyama, M. Shamoto-Nagai, H. Yi, Y. Akao, M. Tanaka, Oxidative stress in mitochondria: decision to survive and death of neurons in neurodegenerative disorder, Mol. Neurobiol. 31 (2005) 81-93.
197. A. Castegna, M. Aksenov, M. Aksenova, V. Thongboonkerd, J.B. Klein, W.M. Pierce, R. Booze, W.R. Markesbery, D.A. Butterfield, Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I. Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1, Free. Radic. Biol. Med. 33 (2002) 562-571.
198. A. Castegna, M. Aksenov, V. Thongboonkerd, J.B. Klein, W.M. Pierce, R. Booze, W.R. Markesbery, D.A. Butterfield, Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II. Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71, J. Neurochem. 82 (2002) 1524-1532.
199. R. Sultana, M. Perluigi, D.A. Butterfield, Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta (1-42), J. Chromatogr. 833 (2006) 3-11.
200. D.A. Butterfield, D. Boyd-Kimball, The critical role of methionine 35 in Alzheimer's amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity, Biochim. Biophys. Acta 1703 (2005) 149-156.
201. D.A. Butterfield, V. Galvan, M.B. Lange, H. Tang, R.A. Sowell, P. Spilman, J. Fombonne, O. Gorostiza, J. Zhang, R. Sultana, et al., In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid Aβ-peptide of APP, Free. Radic. Biol. Med. 48 (2010) 136-144.
202. K. Abe, H.Y. Sakiyama, Y. Nishida, New insight into toxicity due to oligomeric amyloid-β peptide and alpha-synuclein protein induced by Copper(II) ion, Int. J. Chem. 7 (2015) 41-47.
203. J.M. Salbaum, A. Weidemann, H.G. Lemaire, C. LMasters, K. Beyreuther, The promoter of Alzheimer's disease amyloid A4 precursor gene, EMBO. J. 7 (1988) 2807-2813.
204. C.G. Evans, S. Wisén, J.E. Gestwicki, Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro, J. Biol. Chem. 281 (2006) 33182-33191.
205. J. Magrane, R.C. Smith, K. Walsh, H.W. Querfurth, Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons, J. Neurosci. 24 (2004) 1700-1706.
206. S. Ansar, J.A. Burlison, M.K. Hadden, X.M. Yu, K.E. Desino, J. Bean, L. Neckers, K.L. Audus, M.L. Michaelis, B.S. Blagg, A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity, Bioorg. Med. Chem. Lett. 17 (2007) 1984-1990.
207. J.P. Erzberger, J.M. Berger, Evolutionary relationships and structural mechanisms of AAA+ proteins, Annu. Rev. Biophys. Biomol. Struct. 35 (2006) 93-114.
208. A.F. Neuwald, L. Aravind, J.L. Spouge, E.V. Koonin, AAA+: a class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes, Genome. Res. 9 (1999) 27-43.
209. Y. Sanchez, S.L. Lindquist, HSP104 required for induced thermotolerance, Science 248 (1990) 1112-1115.
210. Y. Sanchez, J. Taulien, K.A. Borkovich, S. Lindquist, Hsp104 is required for tolerance to many forms of stress, EMBO. J. 11 (1992) 2357-2364.
211. A.G. Cashikar, M. Duennwald, S.L. Lindquist, A chaperone pathway in protein disaggregation:Hsp26 alters the nature of protein aggregates to facilitate reactivation by Hsp104, J. Biol. Chem. 280 (2005) 23869-23875.
212. J.R. Glover, S. Lindquist, Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins, Cell. 94 (1998) 73-82.
213. P. Goloubinoff, A. Mogk, A.P. Zvi, T. Tomoyasu, B. Bukau, Sequential mechanism of solubilization and refolding of stable protein aggregates by a bichaperone network, Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13732-13737.
214. A. Mogk, T. Tomoyasu, P. Goloubinoff, S. Rudiger, D. Roder, H. Langen, B. Bukau, Identification of thermolabile Escherichia coli proteins: prevention and reversion of aggregation by DnaK and ClpB, EMBO. J. 18 (1999) 6934-6949.
215. D.A. Parsell, J. Taulien, S. Lindquist, The role of heat-shock proteins in thermotolerance, Philos. Trans. R. Soc. Lond. B. Biol. Sci. 339 (1993) 279-285.
216. D.A. Parsell, A.S. Kowal, M.A. Singer, S. Lindquist, Protein disaggregation mediated by heat-shock protein Hsp104, Nature 372 (1994) 475-478.
217. J. Weibezahn, P. Tessarz, C. Schlieker, R. Zahn, Z. Maglica, S. Lee, H. Zentgraf, E.U. Weber-Ban, D.A. Dougan, F.T. Tsai, A. Mogk, B. Bukau, Thermotolerance requires refolding of aggregated proteins by substrate translocation through the central pore of ClpB, Cell. 119 (2004) 653-665.
218. P. Tessarz, A. Mogk, B. Bukau, Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation, Mol. Microbiol. 68 (2008) 87-97.
219. M.C. Lin, T. Mirzabekov, B.L. Kagan, Channel formation by a neurotoxic prion protein fragment, J. Biol. Chem. 272 (1997) 44-47.
220. M. Salmona, G. Forloni, L. Diomede, M. Algeri, L. De Gioia, N. Angeretti, G. Giaccone, F. Tagliavini, O. Bugiani, A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity, Neurobiol. Dis. 4 (1997) 47-57.
221. P. Walsh, Structural Characterization and Membrane Interactions of the Amyloid Peptide PrP (106-126), PhD thesis, University of Toronto Canada, 2013.
222. T. Florio, S. Thellung, C. Amico, M. Robello, M. Salmona, O. Bugiani, F. Tagliavini, G. Forloni, G. Schettini, Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line, J. Neurosci. Res. 54 (1998) 341-352.
223. V. Silei, C. Fabrizi, G. Venturini, M. Salmona, O. Bugiani, F. Tagliavini, G.M. Lauro, Activation of microglial cells by PrP and beta-amyloid fragments raises intracellular calcium through L-type voltage sensitive calcium channels, Brain. Res. 818 (1999) 168-170.
224. S. Thellung, T. Florio, V. Villa, A. Corsaro, S. Arena, C. Amico, M. Robello, M. Salmona, G. Forloni, O. Bugiani, F. Tagliavini, G. Schettini, Apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in rat cerebellar granule cells treated with the prion protein fragment 106-126, Neurobiol. Dis. 7 (2000) 299-309.
225. J. Carimalo, S. Cronier, G. Petit, J.M. Peyrin, F. Boukhtouche, N. Arbez, Y. Lemaigre-Dubreuil, B. Brugg, M.C. Miquel, Activation of the JNK-c-Jun pathway during the early phase of neuronal apoptosis induced by PrP106-126 and prion infection, Eur. J. Neurosci 21 (2005) 2311-2319.
226. S. Thellung, T. Florio, A. Corsaro, S. Arena, M. Merlino, M. Salmona, F. Tagliavini, O. Bugiani, G. Forloni, G. Schettini, Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106-126, Int. J. Dev. Neurosci. 18 (2000) 481-492.
227. G. Comellas, L.R. Lemkau, D.H. Zhou, J.M. George, C.M. Rienstra, Structural intermediates during alpha-synuclein fibrillogenesis on phospholipid vesicles, J. Am. Chem. Soc. 134 (2012) 5090-5099.
228. J.X. Lu, W.M. Yau, R. Tycko, Evidence from solid-state NMR for nonhelical conformations in the transmembrane domain of the amyloid precursor protein, Biophys. J. 100 (2011) 711-719.
229. P.E. Smith, J.R. Brender, A. Ramamoorthy, Induction of negative curvature as a mechanism of cell toxicity by amyloidogenic peptides: the case of islet amyloid polypeptide, J. Am. Chem. Soc. 131 (2009) 4470-4478.
230. P. Walsh, G. Vanderlee, J. Yau, J. Campeau, V.L. Sim, C.M. Yip, S. Sharpe, The mechanism of membrane disruption by cytotoxic amyloid oligomers formed by prion protein(106-126) is dependent on bilayer composition, J. Biol. Chem. 289 (2014) 10419-10430.
231. D. Ebrahimi-Fakhari, L. Wahlster, P.J. McLean, Molecular chaperones in Parkinson's disease-present and future, J. Park. Dis. 1 (2011) 299-320.
232. T. Bartels, J.G. Choi, D.J. Selkoe, α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation, Nature 477 (2011) 107-110.
233. J. Li, V.N. Uversky, A.L. Fink, Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein, Biochemistry 40 (2001) 11604-11613.
234. L.V. Kalia, S.K. Kalia, P.J. McLean, A.M. Lozano, A.E. Lang, α-Synuclein oligomers and clinical implications for Parkinson disease, Ann. Neurol. 73 (2013) 155-169.
235. M.S. Goldberg, P.T. Lansbury Jr., Is there a cause- and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell. Biol. 2 (2000) E115-E119.
236. T.T. Ding, S.J. Lee, J.C. Rochet, P.T. Lansbury Jr., Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes, Biochemistry 41 (2002) 10209-10217.
237. S.D. Zakharov, J.D. Hulleman, E.A. Dutseva, Y.N. Antonenko, J.C. Rochet, W.A. Cramer, Helical alpha-synuclein forms highly conductive ion channels, Biochemistry 46 (2007) 14369-14379.
238. I.F. Tsigelny, P. Bar-On, Y. Sharikov, L. Crews, M. Hashimoto, M.A. Miller, S.H. Keller, O. Platoshyn, J.X. Yuan, E. Masliah, Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by betasynuclein, FEBS. J. 274 (2007) 1862-1877.
239. M. Kostka, T. Högen, K.M. Danzer, J. Levin, M. Habeck, A. Wirth, R. Wagner, C.G. Glabe, S. Finger, U. Heinzelmann, P. Garidel, W. Duan, C.A. Ross, H. Kretzschmar, A. Giese, Single particle characterization of iron-induced pore-forming α-synucleinoligomers, J. Biol. Chem. 283 (2008) 10992-11003.
240. E. Deas, N. Cremades, P.R. Angelova, M. Ludtmann, Z. Yao, S. Chen, M. Horrocks, B. Banushi, D. Little, M. Devine, P. Gissen, D. Klenerman, C. Dobson, T. Wood, S. Gandhi, A.Y. Abramov, Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease, Antioxid. Redox. Signal. 224 (2015) 376-391.
241. P.J. McLean, H. Kawamata, S. Shariff, J. Hewett, N. Sharma, K. Ueda, X.T. Breakefield, B.T. Hyman, TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation, J. Neurochem. 83 (2002) 846-854.
242. K. Uryu, C. Richter-Landsberg, W. Welch, E. Sun, O. Goldbaum, E.H. Norris, C.T. Pham, I. Yazawa, K. Hilburger, M. Micsenyi, B.I. Giasson, N.M. Bonini, V.M. Lee, J.Q. Trojanowski, Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alphasynucleinopathies, Am. J. Pathol. 168 (2006) 947-961.
243. P.K. Auluck, H.Y. Chan, J.Q. Trojanowski, V.M. Lee, N.M. Bonini, Chaperone suppression of alphasynuclein toxicity in a Drosophila model for Parkinson's disease, Science 295 (2002) 865-868.
244. J.B. Leverenz, I. Umar, Q. Wang, T.J. Montine, P.J. McMillan, D.W. Tsuang, J. Jin, C. Pan, J. Shin, D. Zhu, J. Zhang, Proteomic identification of novel proteins in cortical lewy bodies, Brain, Pathol 17 (2007) 139-145.
245. G. Turturici, G. Sconzo, F. Geraci, Hsp70 and its molecular role in nervous system diseases, Biochem. Res. Int. 2011 (2011) (2011) 618127.
246. M.M. Dedmon, J. Christodoulou, M.R. Wilson, C.M. Dobson, Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species, J. Biol. Chem. 280 (2005) 14733-14740.
247. C. Huang, H. Cheng, S. Hao, H. Zhou, X. Zhang, J. Gao, Q.H. Sun, H. Hu, C.C. Wang, Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates, J. Mol. Biol. 364 (2006) 323-336.
248. J. Klucken, T.F. Outeiro, P. Nguyen, B.T. Hyman, Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging, FASEB. J. 20 (2006) 2050-2057.
249. K.C. Luk, I.P. Mills, J.Q. Trojanowski, V.M. Lee, Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly, Biochemistry 47 (2008) 12614-12625.
250. S. Pemberton, K. Madiona, L. Pieri, M. Kabani, L. Bousset, R. Melki, Hsc70 protein interaction with soluble and fibrillar alpha-synuclein, J. Biol. Chem. 286 (2013) 34690-34699.
251. A. Chaari, J. Hoarau-Véchot, M. Ladjimi, Applying chaperones to protein misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease, Int. J. Biol. Macromol. 60 (2013) 196-205.
252. Y. Zhou, G. Gu, D.R. Goodlett, T. Zhang, C. Pan, T.J. Montine, K.S. Montine, R.H. Aebersold, J. Zhang, Analysis of alpha-synuclein-associated proteins by quantitative proteomics, J. Biol. Chem. 279 (2004) 39155-39164.
253. C. Lo Bianco, J. Shorter, E. Régulier, H. Lashuel, T. Iwatsubo, S. Lindquist, P. Aebischer, Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease, J. Clin. Invest 118 (2008) 3087-3097.
254. T.R. Flower, L.S. Chesnokova, C.A. Froelich, C. Dixon, S.N. Witt, Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease, J. Mol. Biol. 351 (2005) 1081-1100.
255. T.F. Outeiro, J. Klucken, K.E. Strathearn, F. Liu, P. Nguyen, J.C. Rochet, B.T. Hyman, P.J. McLean, Small heat shock proteins protect against alphasynuclein-induced toxicity and aggregation, Biochem. Biophys. Res. Commun. 351 (2006) 631-638.
256. H. Ecroyd, J.A. Carver, Crystallin proteins and amyloid fibrils, Cell. Mol. Life. Sci. 66 (2009) 62-81.
257. A. Rekas, C.G. Adda, J. Andrew Aquilina, K.J. Barnham, M. Sunde, D. Galatis, N.A. Williamson, C.L. Masters, R.F. Anders, C.V. Robinson, R. Cappai, J.A. Carver, Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity, J. Mol. Biol. 340 (2004) 1167-1183.
258. C.A. Waudby, T.P. Knowles, G.L. Devlin, J.N. Skepper, H. Ecroyd, J.A. Carver, M.E. Welland, J. Christodoulou, C.M. Dobson, S. Meehan, The interaction of alphaB-crystallin with mature alpha-synuclein amyloid fibrils inhibits their elongation, Biophys. J. 98 (2013) 843-851.
259. L.F. Zhang, Z.W. Zhou, Z.H. Wang, Y.H. Du, Z.X. He, C. Cao, S.F. Zhou, Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells, Drug. Des. Devel. Ther. 9 (2014) 241-272.
260. Z. Fu, D. Aucoin, M. Ahmed, M. Ziliox, W.E. Van Nostrand, S.O. Smith, Capping of aβ42 oligomers by small molecule inhibitors, Biochemistry 53 (2014) 7893-7903.
261. K. Murakami, Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease, Biosci. Biotechnol. Biochem 78 (2014) 1293-1305.
262. S.A. Planque, Y. Nishiyama, S. Sonoda, Y. Lin, H. Taguchi, M. Hara, S. Kolodziej, Y. Mitsuda, V. Gonzalez, H.B. Sait, K.I. Fukuchi, R.J. Massey, R.P. Friedland, B. O'Nuallain, E.M. Sigurdsson, S. Paul, Specific amyloid β clearance by a catalytic antibody construct, J. Biol. Chem. 290 (2015) 10229-10241.
263. Y. Nishiyama, H. Taguchi, M. Hara, S.A. Planque, Y. Mitsuda, S. Paul, Metaldependent amyloid β-degrading catalytic antibody construct, J. Biotechnol. 180 (2014) 17-22.
264. J. Fantini, C. Di Scala, N. Yahi, J.D. Troadec, K. Sadelli, H. Chahinian, N. Garmy, Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's β-amyloid peptides, ACS. Chem. Neurosci. 5 (2014) 216-224.